about
Tuberculosis and cancer: a complex and dangerous liaisonThrombotic Thrombocytopenic Purpura-Haemolytic Uremic Syndrome and pregnancy.Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C.Does hepatitis C virus cause severe liver disease only in people who drink alcohol?Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue.Infections and solid organ transplant rejection: a cause-and-effect relationship?Infections in patients with cancer undergoing chemotherapy: aetiology, prevention, and treatment.Human immunodeficiency virus-associated peripheral neuropathies.Infections and thalassaemia.Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults.Etravirine.Lung infections after cancer chemotherapy.Micafungin - the newest echinocandin.Management of chronic hepatitis B in children: an unresolved issue.Mother-to-child transmission of hepatitis B virus in sub-Saharan Africa: time to act.Liver disease in patients with HIV in sub-Saharan Africa.West African Immigrants and New Patterns of Malaria Imported to North Eastern Italy.Stroke: a realistic approach to a growing problem in sub-Saharan Africa is urgently needed.Immune mechanisms in autoimmune chronic active hepatitis.Immunological aspects of chronic active hepatitis.Dolutegravir monotherapy in HIV-infected naive patients with an HIV-RNA load <100 000 copies/mL: a medium-term follow-up.Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient.An Investigation of Liquid Chromatography-Mass Spectral Attributes and Analytical Performance Characteristics of Tenofovir, Emtricitabine and Efavirenz in Human Plasma.Efavirenz dose reduction in HIV-infected patients: a long-term follow-up.Efficacy of a reduced dose of DARUNAVIR/RTV in a cohort of antiretroviral-naïve and experienced HIV-infected patients: a medium-term follow-up.Comparative chromatography-mass spectrometry studies on the antiretroviral drug nevirapine-analytical performance characteristics in human plasma determination.Can HIV-1 viral interference be used therapeutically?The bacterium that could cause cancer.Neurological complications of HIV infection in pre-HAART and HAART era: a retrospective study.T lymphocyte sensitization to HBcAg and T cell-mediated unresponsiveness to HBsAg in hepatitis B virus-related chronic liver disease.[Markers of viral hepatitis B. Diagnostic, prognostic and therapeutic relevance][Are HBsAg positive viral hepatitis and its fate caused by the genetically determined immune response to the infection?]Cellular immunity to nucleocapsid and pre-S determinants in asymptomatic carriers of hepatitis B virus.Response of uncomplicated falciparum malaria to oral chloroquine and quinine in Burundi highlands.Treatment of Acute Liver Failure in Resource-Constrained Settings without Transplantation Facilities Can Be ImprovedAutoimmune hepatitis type 2 induced by HCV and persisting after viral clearance.Clinical course of infection with hepatitis C.Childhood infections and autoimmune diseases.MHC class I molecules and progression to AIDS.Can antiretroviral therapy be safely interrupted and, if so, when?
P50
Q28239005-F8E9F74F-E052-4CD8-95A3-A22B13D419E2Q33418161-BA7132D2-C1BA-4856-8973-405426142947Q33950169-CDA1C08B-E172-4E8E-9AFA-984A8ABD6DA0Q34683615-70BE59E7-0DA3-46DE-8C8F-C90142B39CACQ34727697-14C4CDC1-388D-4F27-8D9E-E1C3731F4140Q34807471-E9931466-A717-45E7-8896-9230D98734BAQ35557446-021B8517-1ACF-45F7-8853-855449AEEBFDQ36393130-A4B1672F-AD7A-4B96-AAF4-B5188F66A6FAQ36428718-1BBFF3C7-BE6D-45E1-8F94-681686D74791Q36548076-10F827DB-0735-47DA-B224-25960CF45DF1Q37095289-1E6A4390-40D2-407A-9EA9-FC11CE34D3C0Q37345694-49E32870-1C8D-4935-9D86-AF3A7DB36EA1Q37621429-E77D32DF-C60D-410D-82A5-A6A0E8901626Q38215076-EFB5B482-EB72-4F57-A645-F60CCCA6DC81Q38874919-28E7EED7-4961-4021-98C8-248313288E4CQ38928888-0CD9058A-2792-4AFF-88F9-D0ABA5BE8496Q38972217-8B98BAE4-0AF5-4020-93BB-CB9D850892F5Q39143894-D024EA7C-08A0-4181-936F-89BA76551EF5Q39477497-7CC591AF-7C87-4844-AB85-8B99746D2C2BQ39669126-908F5091-A022-4177-8A16-38E3AF5EFDC8Q40260636-B475AC45-A8C0-4AE0-AC97-8EBB696C970FQ40478690-1E36C9C6-7DBC-4AB9-A2E4-EB0DB04ADFBBQ40793702-7EA138D4-5A49-4338-AA8E-749FEFB77763Q40794570-601CCF46-01BC-4E68-8BEF-108CAFE5D7ADQ40794651-01B77D87-3057-4117-8CB0-FB0AC3B698C1Q40795674-88248ABD-F427-4BB9-A072-34B23061D5FCQ40796409-C0B7D9CC-9A9C-4E7A-8FF0-42461C488AFCQ40798389-12E2B87D-96D1-4A0C-83B5-2DFCC54CE724Q41067770-28E30C40-35E7-407D-B78E-F9CEF002FC3CQ41485488-A13B873A-ACE5-4DB4-BFCA-230296C292FCQ41558711-A2BB8C5C-787B-4F1F-B45C-870207332DEEQ41574799-6E5BD7A5-C4F8-4D69-8656-03CDE1617825Q41911519-10683F0D-3EE6-4C2A-B332-6F2D2140A2ECQ41925826-CDB18D3C-0002-4377-A244-618ACCBCDC49Q42428675-11440F51-8104-4D06-ADF6-FA98831BE7A4Q42985293-7E2C444C-1783-49A1-B978-6754A43686BFQ43207595-906FA7D8-9439-4C3C-8971-80216447C6D3Q43457251-E07F2A64-76D3-4FDE-93F9-A6D1A9375E1CQ43606404-8ECF720E-66CF-4974-AB55-359498895B96Q43607040-D56E3349-628B-4418-95F3-1EB05A8E734E
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sandro Vento
@ast
Sandro Vento
@en
Sandro Vento
@es
Sandro Vento
@nl
Sandro Vento
@sl
type
label
Sandro Vento
@ast
Sandro Vento
@en
Sandro Vento
@es
Sandro Vento
@nl
Sandro Vento
@sl
prefLabel
Sandro Vento
@ast
Sandro Vento
@en
Sandro Vento
@es
Sandro Vento
@nl
Sandro Vento
@sl
P106
P21
P31
P496
0000-0003-0084-4062